Alkermes
Develops and sells neuroscience medicines spanning addiction, psychiatry and sleep disorders.
$47.25
After-hours close−0.16 (−0.34%)
At close$47.41(−3.04%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 113.51%Insiders 1.48%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 167.76M · Float 155.14M · 92.5% free float
Institutions13F, as of Jun 30, 2026
436 holders · 190.43M shares · 91 new positions · 232 increased · 136 reduced · 58 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 29.24M | 17.43% | +921.3K | Aug 7, 2026 |
| Baker Bros. Advisors LP | 10.01M | 5.97% | 0 | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 9.49M | 5.66% | −20.3K | Aug 13, 2026 |
| State Street Corp | 9.16M | 5.46% | −304.7K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 7.52M | 4.48% | +87.6K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 6.74M | 4.02% | +2.07M | Aug 14, 2026 |
| Renaissance Technologies LLC | 6.46M | 3.85% | +300.5K | Aug 13, 2026 |
| Geode Capital Management, LLC | 4.48M | 2.67% | +295.6K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 15.80% | 25.64M | 13G | Apr 28, 2025 ↗ |
| Baker Bros. Advisors LP | 6.10% | 10.01M | 13G | Feb 17, 2026 ↗ |
| Vanguard Portfolio Management | 5.80% | 9.65M | 13G | Apr 28, 2026 ↗ |
| Vanguard Capital Management | 5.21% | 8.68M | 13G | Apr 28, 2026 ↗ |
| State Street Corporation | 5.20% | 8.54M | 13G | Nov 10, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Richard F. Pops | director, officer: Director and CEO, Alkermes plc | 1.38M | 0.82% | Feb 6, 2026 |
| Blair Curtis Jackson | officer: EVP, Chief Operating Officer | 241.3K | 0.14% | Feb 27, 2026 |
| David Joseph Gaffin | officer: EVP, CLO, Alkermes, Inc. | 225.5K | 0.13% | Aug 3, 2026 |
| Iain Michael Brown | officer: SVP, Chief Financial Officer | 148.2K | 0.09% | Feb 28, 2025 |
| Shane Cooke | director | 106.7K | 0.06% | May 22, 2026 |
| Christian Todd Nichols | officer: SVP, Chief Commercial Officer | 102.2K | 0.06% | Aug 17, 2026 |
| Craig C. Hopkinson | officer: EVP R&D, Chief Medical Officer | 69.4K | 0.04% | Aug 3, 2026 |
| Brian P. Mckeon | director | 38.5K | 0.02% | May 22, 2026 |
| Richard Gaynor | director | 35.8K | 0.02% | May 22, 2026 |
| Frank Anders Wilson | director | 35.8K | 0.02% | May 22, 2026 |
1 ten-percent owner holds 7.75M shares by Form 4, outside the officers-and-directors figure above · 20 people have not refiled in the last 18 months (1.29M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Christian Todd Nicholsofficer: SVP, Chief Commercial Officer | Sale · 2 lots | 7,576 | $49.23 | 102,193 |
| Aug 3, 2026 | David Joseph Gaffinofficer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $48.58 | 225,456 |
| Aug 3, 2026 | Craig C. Hopkinsonofficer: EVP R&D, Chief Medical Officer | Sale | 9,000 | $48.58 | 69,389 |
| Aug 3, 2026 | nancy lynn MD snydermandirector | Sale | 44,472 | $50.35 | 15,395 |
| Jul 6, 2026 | David Joseph Gaffinofficer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $54.03 | 227,490 |
| Jul 1, 2026 | Craig C. Hopkinsonofficer: EVP R&D, Chief Medical Officer | Sale · 2 lots | 9,000 | $51.51 | 73,389 |
| Jun 12, 2026 | Christopher I. Wrightdirector | Sale | 2,000 | $45.10 | 25,680 |
| Jun 4, 2026 | David Joseph Gaffinofficer: EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $43.05 | 229,524 |
| Jun 1, 2026 | Craig C. Hopkinsonofficer: EVP R&D, Chief Medical Officer | Sale | 9,000 | $41.67 | 77,389 |
| May 29, 2026 | Samuel Joseph Parisiofficer: VP, Finance (Interim PAO) | Sale | 16,217 | $42.36 | 7,717 |
CongressHouse and Senate disclosures
Not reported.